Communication to all

All Rare Disease Clinicians who order Inherited Cancer rare disease testing

All Clinical Genetics Clinicians

**----------------**

**RE: Important change to R216 - Li Fraumeni Syndrome testing**

Dear Colleagues

This communication is to update you around important changes to testing patients for the Clinical Indication R216 Li Fraumeni Syndrome.

Patients eligible for testing using the R216 Li Fraumeni Syndrome clinical indication will now be tested for both the TP53 and the POT1 gene according to the Test Directory:

<https://nhsgms-panelapp.genomicsengland.co.uk/panels/1222/v1.0>

The East GLH team will no longer perform TP53 gene testing alongside Inherited Cancer Clinical Indications.

From the 1st December 2023, all requests for R216 Li Fraumeni Syndrome will be sent for testing and reporting by the designated specialist laboratory in the North East and Yorkshire GLH.

Any questions, please email the Cambridge Laboratory - cuh.geneticslaboratories@nhs.net.

Best wishes

Kate Downes

Lead Scientist for Rare and Inherited Disease - East Genomic Laboratory Hub